Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Climb Bio Inc (CLYM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.87-4.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CLYM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance CLYM116 development with positive safety and modeling data | Climb Bio is advancing CLYM116, an anti-APRIL antibody with promising Phase 1 safety data. | Improving | any major safety issues or trial halts reported | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CLYM is a speculative clinical-stage biotechnology company, not an established earnings compounder. Its thesis is in a watch state: development and financing have progressed, but clinical evidence is still early and confidence in the overall assessment is low.
The evidence snapshot does not provide a valuation measure or a clear account of what investors already expect, so whether CLYM looks cheap, fair, or expensive versus peers cannot be assessed. No fragility gates fired, but that alone does not establish that expectations are low or that valuation risk is limited.
Near term, the company remains loss-making, recent financial performance is neutral, and a smaller-cap, high-miss-rate profile adds risk around the next update. Management has reported early budoprutug and CLYM116 findings and extended stated cash runway into the second half of 2028, though follow-up data and patient confirmation remain pending.
Over the next several years, the thesis depends on whether follow-up and additional clinical data confirm the early signals, and whether Phase 2 enrollment produces useful evidence. Near term, a guidance cut or further weakening in jobs data could weigh on the business outlook, while continued strength from healthcare bellwethers could support sector momentum.
CLYM has made tangible progress on its pipeline and financing, but it remains a high-risk, loss-making company with clinical and execution questions unresolved. The 1-3 year view depends on stronger patient evidence and disciplined delivery. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company is focused on managing operating losses, which were $15.2M in Q1 2026, improving from prior quarters. |
| Intact |
| operating losses increase above $15M per quarter persistently |
Operating income: $-15.359M FY2026-Q2; GAAP. Published target: operating loss improves or stays below $15M per quarter next 4 quarters. Target period is not explicitly aligned with this observation. Aug 6, 2026-15,359,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Positive clinical and modeling news on pipeline drugs | A supporting condition in Climb Bio Inc's published investment case. The stated target is at least one positive clinical or modeling update per quarter. | Improving | no positive updates or multiple negative news events in 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.05 → $-0.99 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.05 | $888,890 | 10 / 11 |
| 2026-07-25 | $-1.05 | $888,890 | 10 / 11 |
| 2026-07-26 | $-1.05 | $888,890 | 10 / 11 |
| 2026-07-27 | $-1.05 | $888,890 | 10 / 11 |
| 2026-07-28 | $-1.12 | $0 | 9 / 14 |
| 2026-07-29 | $-1.12 | $0 | 9 / 14 |
| 2026-07-30 | $-1.05 | $888,890 | 10 / 11 |
| 2026-07-31 | $-1.05 | $888,890 | 10 / 11 |
| 2026-08-01 | $-1.05 | $888,890 | 10 / 11 |
| 2026-08-02 | $-1.13 | $0 | 8 / 13 |
| 2026-08-03 | $-1.05 | $888,890 | 10 / 11 |
| 2026-08-04 | $-1.05 | $888,890 | 10 / 11 |
| 2026-08-05 | $-1.05 | $888,890 | 10 / 11 |
| 2026-08-06 | $-1.09 | $0 | 9 / 13 |
| 2026-08-07 | $-1.03 | $750,000 | 10 / 11 |
| 2026-08-08 | $-1.12 | $0 | 9 / 12 |
| 2026-08-09 | $-1.12 | $0 | 9 / 12 |
| 2026-08-10 | $-1.03 | $750,000 | 10 / 11 |
| 2026-08-11 | $-1.03 | $750,000 | 10 / 11 |
| 2026-08-12 | $-1.06 | $937,500 | 9 / 8 |
| 2026-08-13 | $-1.03 | $750,000 | 10 / 11 |
| 2026-08-14 | $-1.03 | $750,000 | 10 / 11 |
| 2026-08-15 | $-1.03 | $750,000 | 10 / 14 |
| 2026-08-16 | $-1.03 | $750,000 | 10 / 14 |
| 2026-08-17 | $-1.03 | $750,000 | 10 / 14 |
| 2026-08-18 | $-1.03 | $750,000 | 10 / 14 |
| 2026-08-19 | $-1.03 | $750,000 | 10 / 14 |
| 2026-08-20 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-21 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-22 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-23 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-24 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-25 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-26 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-27 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-28 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-29 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-30 | $-1.00 | $833,333 | 10 / 14 |
| 2026-08-31 | $-1.00 | $833,333 | 10 / 14 |
| 2026-09-01 | $-1.00 | $833,333 | 10 / 14 |
| 2026-09-02 | $-1.00 | $833,333 | 10 / 14 |
| 2026-09-03 | $-1.00 | $833,333 | 11 / 14 |
| 2026-09-04 | $-0.98 | $750,000 | 11 / 14 |
| 2026-09-05 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-06 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-07 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-08 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-09 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-10 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-11 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-12 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-13 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-14 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-15 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-16 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-17 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-18 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-19 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-20 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-21 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-22 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-23 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-24 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-25 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-26 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-27 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-28 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-29 | $-0.98 | $750,000 | 11 / 15 |
| 2026-09-30 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-01 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-02 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-03 | $-1.00 | $750,000 | 11 / 15 |
| 2026-10-04 | $-1.00 | $750,000 | 11 / 15 |
| 2026-10-05 | $-1.00 | $750,000 | 11 / 15 |
| 2026-10-06 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-07 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-08 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-09 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-10 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-11 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-12 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-13 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-14 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-15 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-16 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-17 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-18 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-19 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-20 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-21 | $-0.98 | $750,000 | 11 / 15 |
| 2026-10-22 | $-0.97 | $763,636 | 11 / 15 |
| 2026-10-23 | $-0.97 | $763,636 | 11 / 15 |
| 2026-10-24 | $-0.97 | $763,636 | 11 / 15 |
| 2026-10-25 | $-0.97 | $763,636 | 11 / 15 |
| 2026-10-26 | $-0.97 | $763,636 | 11 / 15 |
| 2026-10-27 | $-0.97 | $763,636 | 11 / 15 |
| 2026-10-28 | $-0.99 | $763,636 | 11 / 15 |
| 2026-10-29 | $-0.99 | $763,636 | 11 / 15 |
| 2026-10-30 | $-0.99 | $763,636 | 11 / 15 |
| 2026-10-31 | $-0.99 | $763,636 | 11 / 15 |
| 2026-11-01 | $-0.99 | $763,636 | 11 / 15 |
| 2026-11-02 | $-0.99 | $763,636 | 11 / 15 |
| 2026-11-03 | $-0.99 | $763,636 | 11 / 15 |
| 2026-11-04 | $-0.99 | $763,636 | 11 / 15 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 15 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.